Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H12ClNO2.ClH |
Molecular Weight | 250.122 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.NC[C@H](CC(O)=O)C1=CC=C(Cl)C=C1
InChI
InChIKey=WMNUVYYLMCMHLU-QRPNPIFTSA-N
InChI=1S/C10H12ClNO2.ClH/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14;/h1-4,8H,5-6,12H2,(H,13,14);1H/t8-;/m0./s1
Molecular Formula | C10H12ClNO2 |
Molecular Weight | 213.661 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Arbaclofen (STX209, R-baclofen), a selective agonist of GABA-B receptors, has been investigated in clinical trials for the treatment of autism spectrum disorder ASD, phase II and for the treatment of patients with fragile X syndrome in phase III. As a result, the drug did not meet the primary outcome of improved social avoidance in FXS in either study. In spite of positive results in some children with ASD, further study will be needed to replicate and extend these initial findings. Arbaclofen has also been investigated in phase III clinical trials as a treatment for spasticity due to multiple sclerosis.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2111463 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22993295 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28616094
5 mg BID to 15 mg TID
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:18:46 GMT 2025
by
admin
on
Mon Mar 31 18:18:46 GMT 2025
|
Record UNII |
8703929ITD
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29696
Created by
admin on Mon Mar 31 18:18:46 GMT 2025 , Edited by admin on Mon Mar 31 18:18:46 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
63701-55-3
Created by
admin on Mon Mar 31 18:18:46 GMT 2025 , Edited by admin on Mon Mar 31 18:18:46 GMT 2025
|
PRIMARY | |||
|
8703929ITD
Created by
admin on Mon Mar 31 18:18:46 GMT 2025 , Edited by admin on Mon Mar 31 18:18:46 GMT 2025
|
PRIMARY | |||
|
44601
Created by
admin on Mon Mar 31 18:18:46 GMT 2025 , Edited by admin on Mon Mar 31 18:18:46 GMT 2025
|
PRIMARY | |||
|
C90888
Created by
admin on Mon Mar 31 18:18:46 GMT 2025 , Edited by admin on Mon Mar 31 18:18:46 GMT 2025
|
PRIMARY | |||
|
m2200
Created by
admin on Mon Mar 31 18:18:46 GMT 2025 , Edited by admin on Mon Mar 31 18:18:46 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID40213112
Created by
admin on Mon Mar 31 18:18:46 GMT 2025 , Edited by admin on Mon Mar 31 18:18:46 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |